BBC News spoke to people who are already paying to access Mounjaro, or are hoping to access it through the NHS, about their views on the announcement. Alix ...
The NHS spending watchdog has recommended Mounjaro – also known as tirzepatide and made by Eli Lilly – for those with a body mass index (BMI) of more than ...
That includes high blood pressure, elevated cholesterol, obstructive sleep apnoea, cardiovascular disease, and prediabetes or type 2 diabetes. It's a narrower ...
But there have been growing concerns about misleading statements on the medications' safety and risk of severe injuries, including stomach paralysis and ...
Fewer than 10% of patients in England who are eligible will initially be able to access it on the NHS.
Mounjaro, a drug for type 2 diabetes, is being rolled out by the NHS to help weight loss - but what is it and how does it compare to Ozempic?
Eligible people may have to wait years for the 'King Kong of weight-loss drugs'
Fewer than 10 per cent of patients in England who are eligible will initially be able to access it on the NHS.
The National Institute for Health and Care Excellence (Nice) said it was a 'difficult' decision.
The National Health Service (NHS) in England will make a new weight loss drug available next year – but fewer than 10 per cent of eligible people will have ...
The “first” NHS Mounjaro patients of a possible 3.4 million are set to receive the weight loss jab by March 2025, NICE has revealed in new draft guidance, ...
Weight loss jab tirzepatide – commonly sold under the brand name Mounjaro – is set to become available via the NHS for eligible patients in England.